These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33982511)

  • 1. [Application of objective performance criteria in post-marketing evaluation schemes of traditional Chinese medicine].
    Zhang C; Yu MK; Tang JP; Huo YQ; Fei YT; Wang ZF; Xu Q; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1999-2003. PubMed ID: 33982511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Exploration and practice of post-marketing survival benefit evaluation of Chinese patent medicine for cancer].
    Xu BW; Wu JY; Li J; Zhang Y; Cao LC; Zhang XX; Gao RK
    Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1980-1987. PubMed ID: 33982508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Technical specification for re-evaluation of post-marketing clinical effectiveness of traditional Chinese medicine (first draft)].
    Zhao Y; Yang YY; Wang YX; Yang HM; Wu SX
    Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3211-3215. PubMed ID: 30200720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guidelines for economic evaluation of post-marketing Chinese patent medicine].
    Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guidelines for post-marketing research on clinical effectiveness of Chinese patent medicines].
    Wang ZF; Xie YM; Tang JY; Zhang JH; Sun X; Yang ZQ
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(3):842-848. PubMed ID: 38621888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evidence map analysis of randomized controlled trial of commonly used Chinese patent medicines in treatment of type 2 diabetes mellitus in recent five years].
    Jiang JJ; Jing YY; Li YY; Yang YN; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1102-1112. PubMed ID: 38621917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Systematic review on methodology of randomized controlled trials of post-marketing Chinese patent drugs for treatment of type 2 diabetes].
    Ma LX; Wang YY; Li XX; Liu JP
    Zhong Xi Yi Jie He Xue Bao; 2012 Mar; 10(3):279-92. PubMed ID: 22409917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thoughts on post-marketing evaluation of classical Chinese patent medicines based on clinical value].
    Song Z; Wang ZF; Wu Y; Xie YM; Yang YF; Xu Y
    Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1988-1993. PubMed ID: 33982509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Post-marketing reevaluation for potential quality risk and quality control in clinical application of traditional Chinese medicines].
    Li HJ; He LY; Liu BY
    Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2461-3. PubMed ID: 26591543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Key points of post-marketing evaluation of classic traditional Chinese medicine prescriptions based on combination of disease and syndrome].
    Wang XL; Zhu MJ; Wang JR; Li B; Yu R; Peng GC; Zhao QF; Wang YX
    Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):2004-2009. PubMed ID: 33982512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
    Yang W; Xie Y; Zhuang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Conception and practice of "three dimensions and four stages" clinical orientation method for post-marketing evaluation of traditional Chinese medicine].
    Wang ZF; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1967-1972. PubMed ID: 33982506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of add-on-design in post-marketing evaluation of traditional Chinese medicine].
    Yang ZQ; Tang HM; DU YP; Tang YQ; Yuan TH; Wang ZF; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1994-1998. PubMed ID: 33982510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Core elements of safety monitoring report of medicines(Chinese patent medicines)].
    Wang GQ; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4483-4487. PubMed ID: 28936827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
    Shang HC; Zhang BL; Li YP
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evidence-based Chinese medicine：theory and practice].
    Zhang JH; Li YP; Zhang BL
    Zhongguo Zhong Yao Za Zhi; 2018 Jan; 43(1):1-7. PubMed ID: 29552804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advantages and disadvantages of production quality of Fufang Danshen Prescription based on high-quality Chinese patent medicine evaluation criteria].
    Zhao AY; Liu YP; Chen S; Guo C; Liu YZ; Wang ZG; Liu Y; Liu A
    Zhongguo Zhong Yao Za Zhi; 2022 Sep; 47(17):4814-4822. PubMed ID: 36164888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics].
    Jiang J; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2811-2. PubMed ID: 22292372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research on evaluation criteria over quality as core index of high grade Chinese patent medicine].
    Liu Y; Yu HC; Zhang J; Chen C; Cheng JT; Song ZH; Liu A
    Zhongguo Zhong Yao Za Zhi; 2018 Nov; 43(21):4356-4360. PubMed ID: 30583641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.